Pharmacokinetics and Toxicity of VP 16 (Etoposide) in Patients with Gestational Choriocarcinoma and Malignant Teratoma
18 patients with malignant teratoma each received VP 16 in combination with cyclophosphamide and actinomycin D, and 7 patients with gestational choriocarcinoma recieved VP 16 alone. VP16 (100mg/m2) was administered on 5 consecutive days as an i.v. infusion of 30 minutes. Blood samples were taken immediately before and after infusion. Serum concentrations of the drug were measured by HPLC and are shown below.